Primary objective:~To investigate the safety and efficacy of CD7 CAR-T cells in the treatment of patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL).~Secondary objective:~To assess the patient's quality of life after receiving the treatment.
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of T cells expressing CD7 chimeric antigen receptors (referred to as BT-007 CAR-T cells) in patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL).